ARTICLE | Finance
How Apogee will test the IPO market’s appetite for preclinical risk
Backed by Fairmount Funds and Venrock and spun out of Paragon, the young start-up has an experienced CFO and is aiming for familiar targets
June 23, 2023 9:34 PM UTC
Apogee’s bid to go public on NASDAQ will test the market’s appetite for a preclinical biotech — likely the first in eight months to seek an offering larger than $10 million — albeit one with a few traits that make it a less risky play than some of its early-stage peers.
Apogee Therapeutics Inc. would follow onto NASDAQ the three clinical biotechs that have raised at least $25 million this year. A fourth, Turnstone Biologics Inc., is also in the queue...